- Published: April 2012
- Region: Japan
Anti-cancer Drugs Market in Japan 2011-2015
- Published: April 2012
- Region: Japan
- 35 pages
- Infiniti Research Limited
TechNavio’s analysts forecast the Anti-cancer Drugs market in Japan to grow at a CAGR of 11.1 percent over the period 2011–2015. One of the key factors contributing to this market growth is the increase in the number of cancer patients in the country. The Anti-cancer Drugs market in Japan has also been witnessing the trend of using a combination of cancer therapies for treatment. However, stringent government regulations in Japan could pose a challenge to the growth of this market.
TechNavio’s report, the Anti-cancer Drugs Market in Japan 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Japan; it discusses the Anti-cancer drugs market in the Japan landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Roche Pharmaceuticals Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Co., and AstellasPharma Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Geographical Segmentation
06. Rate of Incidence and Prevalence
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 Roche Pharmaceuticals Inc.
14.2 Novartis International AG
14.3 Takeda Pharmaceutical Co. Ltd.
14.4 Eli Lilly and Co.
14.5 Astellas Pharma Inc.
15. Other Reports in this Series
List of Exhibits:
Exhibit 1: Anti-cancer Drugs Market in Japan 2011–2015 (US$ billion)
Exhibit 2: Anti-cancer Drugs Market in the APAC Region by Geographical Segmentation 2011
TechNavio Announces the Publication of its Report – Anti-cancer Drugs Market in Japan 2011–2015
TechNavio today launched its Anti-cancer Drugs Market in Japan 2011–2015 report based on an in-depth study focusing exclusively on the Japanese market. The report aims to aid decision makers’ understanding of the present and the future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said, “Poor awareness of cancer and its prevention among people and consequent late stage detection of most cancers in patients is quite common in Japan. Healthcare systems in Asia have recognized this problem and are working to educate the public on the causes of cancer, as well as to improve their facilities for treating the disease. For instance, Eisai has established a Japan-based oncology promotion framework, under which oncology information specialists have been assigned to each prefecture in the case of japan and approximately 1,400 medical representatives have been stationed around the country to provide information on anti-cancer therapies.”
According to the report, the Pharmaceutical market in Japan differs noticeably from western markets in several aspects of the regulatory areas for the approval of drugs, and it continues to undergo significant changes. In Japan, both regional and global vendors have to undergo a long and rigorous process for approvals and licenses to market.
The report also reveals that one of the major challenges in this market is the presence of counterfeit anti-cancer drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.